advertisement
Hedengran A 27
Showing records 1 to 25 | Display all abstracts from Hedengran A100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Freiberg JC
Journal of clinical medicine 2022; 11:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Thein AS
American Journal of Ophthalmology 2022; 241: 190-197
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Hedengran A
Acta Ophthalmologica 2022; 100: 819-827
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Hedengran A
American Journal of Ophthalmology 2022; 241: 190-197
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Freiberg JC
Acta Ophthalmologica 2022; 100: 819-827
100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Hedengran A; Heegaard S
Journal of clinical medicine 2022; 11:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Azuara-Blanco A
American Journal of Ophthalmology 2022; 241: 190-197
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Hansen PM; Jacobsen J
Acta Ophthalmologica 2022; 100: 819-827
100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Petrovski G
Journal of clinical medicine 2022; 11:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Arita R
American Journal of Ophthalmology 2022; 241: 190-197
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Jacobsen J
Acta Ophthalmologica 2022; 100: 819-827
100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Jacobsen J
Journal of clinical medicine 2022; 11:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Cvenkel B
American Journal of Ophthalmology 2022; 241: 190-197
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Larsen SW
Acta Ophthalmologica 2022; 100: 819-827
100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Jacobsen J
Journal of clinical medicine 2022; 11:
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Harloff-Helleberg S
Acta Ophthalmologica 2022; 100: 819-827
100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Cvenkel B
Journal of clinical medicine 2022; 11:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Gazzard G
American Journal of Ophthalmology 2022; 241: 190-197
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Freude K
Acta Ophthalmologica 2022; 100: 819-827
100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Kolko M
Journal of clinical medicine 2022; 11:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Heegaard S
American Journal of Ophthalmology 2022; 241: 190-197
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Boix-Lemonche G
Acta Ophthalmologica 2022; 100: 819-827
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
de Paiva CS
American Journal of Ophthalmology 2022; 241: 190-197
100540 Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
Petrovski G
Acta Ophthalmologica 2022; 100: 819-827
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Petrovski G; Prokosch-Willing V
American Journal of Ophthalmology 2022; 241: 190-197
